Sun Pharma stock: Sun Pharma schedules October 30 results for Sun Pharma stock

Published on 10/20/2026 at 16:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q1 fiscal 2027 revenue rose 10.50 percent. Sun Pharma stock costs INR 1,743.00 on October 19, 2026, down 0.90 percent versus its prior close.

Reporting date October 30, 2026

Sun Pharma will announce results for the quarter ended September 30 on October 30, 2026.
Q1 fiscal 2027 revenue rose 10.50 percent to INR 153.00 billion.
Sun Pharma stock costs INR 1,743.00 on October 19, 2026, down 0.90 percent versus its prior close.

Sun Pharma, INE044A01036, Illustration mit AI erstellt.

Sun Pharma (ISIN INE044A01036) will announce results for the quarter ended September 30 on October 30, 2026, according to EconoTimes. Sun Pharma closed at INR 1,743.00 on the NSE on October 19, 2026 at 3:29 p.m. IST, down 0.90 percent from INR 1,758.80.

Revenue growth remains visible

In the first quarter of fiscal 2027, Sun Pharma reported revenue of INR 153.00 billion, up 10.50 percent year on year, while reported profit after tax reached INR 29.11 billion, up 26.40 percent. These figures were carried in a September 21, 2026 research update by Geojit Investments and published by DSIJ.

The same report put adjusted earnings per share at INR 12.40 for the quarter, up 3.30 percent year on year. It also said the global specialty business represented 22.00 percent of sales, giving investors a second growth measure beyond consolidated revenue.

Price frame on October 19

Sun Pharma's NSE price stood 14.84 percent above its 52-week low of INR 1,583.70 and 14.85 percent below its 52-week high of INR 2,046.90. The October 19 volume was 829,135 shares, while the market capitalization was INR 4.2 trillion.

The valuation was 34.58 times earnings on October 19. For comparison, Dr. Reddy's Laboratories traded at 31.29 times earnings with a market capitalization of INR 1.0 trillion, while Cipla traded at 31.75 times earnings with a market capitalization of INR 1.1 trillion. Their daily changes were plus 0.77 percent and minus 0.08 percent, respectively.

Valuation and dates

The next results date is the immediate calendar marker for Sun Pharma stock. The company is also scheduled to announce postal-ballot results on or before November 3, 2026, under a notice published by Sun Pharma.

What could pressure the next margin update? Business Standard reported on October 14, 2026 that the first-quarter operating margin moderated to 29.00 percent from 31.10 percent a year earlier, while US generics remained exposed to competition and pricing pressure. The report also cited an 8.40 percent share of the Indian pharmaceutical market.

Comparison with peers

Sun Pharma: down 0.90 percent, P/E 34.58, market capitalization INR 4.2 trillion.

Dr. Reddy's Laboratories (NSE, INR): up 0.77 percent, P/E 31.29, market capitalization INR 1.0 trillion.

Cipla (NSE, INR): down 0.08 percent, P/E 31.75, market capitalization INR 1.1 trillion.

Results date sets the next test

October 30 will put the latest revenue growth, specialty contribution and margin trend on one page. The contrast between 10.50 percent revenue growth and the 29.00 percent operating margin makes profitability the central figure to watch.

Sun Pharma closed at INR 1,743.00 on the NSE on October 19, 2026 at 3:29 p.m. IST, down 0.90 percent versus INR 1,758.80.